Skip to content

← All developments

Tennessee Attorney General · August 5, 2026 · Primary source

Tennessee Secures Multistate Settlement in Principle with Sandoz Over Alleged Generic Drug Price-Fixing

Score 70PRIMARYregulatoryState AGTNCT

Summary

A bipartisan coalition of 43 states and territories announced a $469 million settlement in principle with Sandoz Inc. to resolve allegations that the generic drug manufacturer conspired to inflate and manipulate generic drug prices, reduce competition, and restrain trade. Tennessee AG Jonathan Skrmetti joined the announcement on August 5, 2026. The settlement remains subject to court approval. The action arises from state antitrust and consumer protection claims targeting the generic pharmaceutical market.

What this may mean

Sandoz faces approximately $469 million in payments to resolving states and territories if the settlement receives court approval. The action implicates generic drug manufacturers' pricing and market-allocation conduct under state antitrust laws, signaling continued multistate AG coordination on pharmaceutical pricing. Payors, PBMs, and health systems that purchase generic drugs are the downstream beneficiaries of this enforcement posture.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.

Related items